Results 81 to 90 of about 5,671 (151)

Drug-Induced Liver Injury Caused by Abiraterone Acetate in Patients With Prostate Cancer. [PDF]

open access: yesCureus
Nakagami Y   +7 more
europepmc   +1 more source

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. [PDF]

open access: yesNat Med
Attard G   +22 more
europepmc   +1 more source

FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. [PDF]

open access: yesClin Cancer Res
Maguire WF   +21 more
europepmc   +1 more source

Evaluation of exposure-response-safety relationship of model-informed low-dose 500 mg abiraterone acetate in prostate cancer patients. [PDF]

open access: yesCancer Commun (Lond)
Chiong E   +15 more
europepmc   +1 more source

Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC. [PDF]

open access: yesFuture Oncol
Castro E   +7 more
europepmc   +1 more source

The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate. [PDF]

open access: yesProstate
Shi Y   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy